Bioenvision Enters into General Services Agreement with RRD International.Business Editors NEW YORK--(BUSINESS WIRE)--May 8, 2003 Bioenvision, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIOV) today announced that in April 2003, the Company entered into a general services agreement with RRD RRD R.R. Donnelley RRD Round Robin Database (a system to store and display time-series data) RRD Removable Rigid Disk RRD Rhegmatogenous Retinal Detachment RRD Radio Regulatory Department RRD Regimental Reconnaissance Detachment International, LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control . Based on the agreement, RRD will advise and assist Bioenvision with its global development strategy and clinical trial design and management for its lead drugs, clofarabine and trilostane (Modrenal(TM)), as well as for its Oligon anti-infective technology. "We are delighted to have added these knowledgeable product development experts to our operating team operating team Surgery The participants–surgeons, nurses, etc–in a sterile surgical procedure performed under general–less commonly, local anesthesia ," said Dr. Christopher B. Wood, Chairman and Chief Executive Officer of Bioenvision. "Based on RRD's experience and proven performance in developing drugs and related technologies, we believe their support will help expedite our development strategy and maximize the potential of our lead products." Clofarabine is currently undergoing Phase II clinical trials for the treatment of acute leukemia acute leukemia Hematology A rapidly progressive malignancy of sudden onset, characterized by an uncontrolled 'clonal' proliferation of immature WBCs which replace BM and spill into the peripheral circulation; untreated AL may be fatal in wks to months. in children and adults, and is also being evaluated in solid tumors. Modrenal(TM) is approved for marketing in the United Kingdom for the treatment of advanced postmenopausal post·men·o·paus·al adj. Of or occurring in the time following menopause. postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr breast cancer and the company expects to begin U.S. clinical trials in prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. in 2003. The OLIGON antimicrobial material has been licensed to a third party for use in central venous and pulmonary artery catheters and is currently generating revenues from sales. About RRD International RRD provides highly experienced strategic and operational support for product development programs in the biotech, pharmaceutical and medical device industries. RRD follows a unique risk-sharing partnership model, which aligns its success with that of its partner companies. About Bioenvision Bioenvision's (OTCBB: BIOV.OB) primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine, Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the OLIGON technology, an advanced biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer. that has been approved for certain indications by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in the U.S. Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion